Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sibia Neurosciences Inc.

Division of Merck & Co. Inc.

Latest From Sibia Neurosciences Inc.

Shrinking Discovery

The theory that smaller is better--as it is has been in the computer industry--is now driving enthusiasm for nanotechnology, a term that refers to the process of manipulating materials at atomic scale. New players are crowding under this hot rubric, including many working at not nearly so small a scale. Drug discovery methods are among the most compelling near-term nano-applications, but start-ups face challenges like those met by micro-scale pioneers Affymetrix and Caliper. Firms must show they can physically create systems they describe, and that teeny discovery methods actually matter for bench scientists. Business models in this emerging sector reflect the difficulties of harnessing novel science in ways that will satisfy drugmakers who've become extra-tough customers under pressure to deliver commercial results in a shifting, financially depressed market. Some start-ups are working on a fee-for-service basis, on specific projects that address customers' immediate needs. Others are deliberately doing development work on their own, gathering data to attract partnerships that may prove all the more rewarding because of their measured starts.
BioPharmaceutical Strategy

Playing the High-Stakes Pharma Game, Part I

The rise in valuations of Big Biotech is due in large part to the fact that they're seen as affordable acquisition candidates for Big Pharmas in search of late-stage products. The plethora of early-stage biotech consolidation is, in contrast, generally a choice of last resort for otherwise unfinanceable companies who also can't sign worthwhile pharma deals. But the attention on late-stage programs offers opportunities for companies, like Pfizer, to strike platform technology deals which transfer technology, royalty free, from biotech to drug firm. The deals aren't cheap but these structures, impossible when platform deals were popular, allow Pfizer much greater research freedom.
BioPharmaceutical Strategy

The Price of Distress Sales

The small-cap intra-biotech M&A deals now occurring are, at least for sellers, always transactions of last resort--done at extraordinarily dilutive prices. Big Biotech acquisitions, on the other hand, are done for big premiums. In this column, we show the various discounts and premiums biotech acquirers are paying.
BioPharmaceutical Strategy

A New Paradigm for Patenting

Revolutionary scientific advances and, an increasingly competitive landscape, will drive pharmaceutical companies to fashion a more strategic and integrated role for patenting in their organizations.
BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • William T Comer, PhD, Pres. & CEO
    Thomas A Reed, VP, Fin. & Admin., CFO
    Michael Harpold, PhD, VP, Research
  • Contact Info
  • Sibia Neurosciences Inc.
    Phone: (619) 452-5892
    505 Coast Blvd. South
    Ste. 300
    La Jolla, CA 92037-4641
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register